Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Harbour BioMed Reports Positive Data from Myasthenia Gravis Trial

publication date: Jul 6, 2021

Harbour BioMed reported positive topline results from a China Phase II trial of batoclimab in patients with myasthenia gravis (gMG), an autoimmune disease. Batoclimab is a fully human anti-FcRn mAb that blocks FcRn-IgG interactions, accelerating the degradation of autoantibodies. HBM expects the candidate will treat pathogenic IgG-mediated autoimmune diseases. HBM is a novel drug discovery/development company with operations in the US, Rotterdam and Suzhou. More details....

Stock Symbol: (HK: 02142)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.